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ABSTRACT 
Purpose. Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in 
just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene 
encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other 
discrete developmental processes. The genetic alterations described so far are mainly 
microdeletions. The present study was aimed at increasing our understanding of LAMSHF, its 
clinical and genetic spectrum, and the pathophysiological mechanisms involved. 
Methods. Clinical and genetic data were collected through GeneMatcher and clinical or genetic 
networks for forty-one novel patients harboring various types of SOX5 alterations. Functional 
consequences of selected substitutions were investigated. 
Results. Microdeletions and truncating variants occurred throughout SOX5. In contrast, most 
missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter 
variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas 
missense variants located outside the high-mobility-group domain did not. Clinical 
manifestations and severity varied among patients. No clear genotype/phenotype correlations 
were found, except that missense variants outside the high-mobility-group domain were 
generally better tolerated. 
Conclusion. This study extends the clinical and genetic spectrum associated with LAMSHF 
and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual 
disability, language delay, and other clinical features. 
 
KEYWORDS 
Autism; developmental delay; intellectual disability; epilepsy; missense variants. 
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INTRODUCTION 
The SOX protein family is made of transcription factors harboring a high-mobility-group 
(HMG) domain at least 50% similar to that of SRY (encoded by the sex-determining region on 
the Y chromosome).1 This domain mediates DNA binding and bending, nuclear trafficking, and 
protein-protein interactions. The 20 SOX proteins existing in humans and other mammals fall 
into eight groups (SOXA to SOXH) based on sequence identity within and outside this 
domain.2,3 Most have been shown in animal models to play pivotal roles in determining the 
lineage choice, differentiation program and survival capacity of discrete cell types, such that as 
a whole the SOX family controls many crucial biological processes, including sex 
determination, neurogenesis, and skeletogenesis.1 In humans, pathogenic variants in half of the 
SOX genes were shown to date to cause developmental disorders.4 For example, SRY variants 
cause XY sex reversal (MIM 400045 and 400046);5 SOX9 variants cause campomelic dysplasia 
with or without XY sex reversal (MIM 114290);5 SOX18 variants cause hypotrichosis-
lymphedema-telangiectasia syndrome (MIM 607823 and 137940);6 SOX4 and SOX11 (MIM 
615866) variants cause Coffin-Siris syndrome-like syndromes.7,8 Most pathogenic variants are 
de novo and, except for SRY, result in dominant disorders because of gene haploinsufficiency. 
 Lamb-Shaffer syndrome (LAMSHF, MIM 616803) was initially described as a 
condition caused by de novo deletions ranging from a few kilobases to several megabases and 
including at least part of SOX5.9 LAMSHF is clinically characterized by developmental delays, 
language and motor deficits, intellectual disability, behavioral disturbances including autistic 
traits, and other, partially penetrant features.9-12 SOX5 is located on chromosome 12p12.1 and 
gives rise to at least five transcript isoforms through expression from different promoters, 
alternative start site usage and alternative pre-mRNA splicing. The longest isoform 
(NM_006940) encodes a 763-amino-acid protein (originally referred to as L-SOX5, but more 
recently and henceforward called SOX5) and is the predominant brain isoform.13 The shortest 
isoform (NM_178010) encodes a protein corresponding to the L-SOX5 C-terminal half and is 
testis-specific. All long protein isoforms contain the same functional domains and are 
collectively critical in mouse development.14 Sox5-/- mice are born with lethal skeletal 
malformations and with defective deep-layer cortical projection neurons, while Sox5+/- mice 
have a normal lifespan and no obvious abnormalities.15-18 
 To date, only a few SOX5 point variants, mostly introducing premature termination 
codons, have been reported in LAMSHF patients19-21 or in large genetic studies of 
developmental disorders without detailed clinical descriptions.22-25 In this study, we describe 
41 unpublished patients carrying various SOX5 deletions and point variants, including 16 with 
missense variants. We delineate more precisely the clinical spectrum associated with SOX5 
alterations, aim at establishing genotype/phenotype correlations, and explore pathogenicity of 
selected variants using both in silico and functional approaches. 
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METHODS 
Human subjects 
We collected clinical and molecular data from patients with SOX5 microdeletions or point 
variants through GeneMatcher,26 DECIPHER27 (patient ID: 333039, 340665, 271393, 264625), 
and clinical networks. Referring physicians used standard developmental scales and filled out 
a table with detailed developmental, neurological and behavioral history, including imaging 
and electroencephalogram (EEG) data where available. The study was approved by INSERM 
(RBM C12-06). We obtained informed written consent for all genetic studies as well as for the 
use of photographs shown in Fig. 2g. 
 
Genetic studies  
Diagnostic laboratories performed genetic tests on blood samples using microarrays or next-
generation sequencing (Supplementary Table 1). SOX5 variants and deletions were validated 
and searched for in parents using Sanger sequencing and fluorescent in situ hybridization 
(FISH) or real-time PCR, respectively. SOX5 variants were described based on the longest 
isoform (NM_006940.4) using Alamut 2.11 (Interactive Biosoftware, France) and Human 
Genome Variation Society guidelines (www.hgvs.org/mutnomen). The InterVar interface 
(http://wintervar.wglab.org/) was used to classify SOX5 variants with adjusted criteria 
according to American College of Medical Genetics and Genomics (ACMG) 
recommendations.28,29 Combined annotation dependent depletion (CADD) scores30 were 
calculated for each variant (Supplementary Table 1). SOX5 isoforms and promoters and other 
SOX sequences were retrieved from NCBI (https://www.ncbi.nlm.nih.gov/) and Fantom5 
databases (http://fantom.gsc.riken.jp/5/) and sequences were aligned using ClustalW 
(MacVector16 software). The effects of missense variants on protein structure and function 
were predicted using HOPE31 and Swiss-Model.32 SOX5 variants were queried in human 
populations using gnomAD (https://gnomad.broadinstitute.org/). Data were statistically 
analyzed using Fisher’s exact and Wilcoxon-Mann Whitney tests. 
 
SOX5 plasmids 
Expression plasmids for the longest SOX5 isoform and variants thereof were generated in the 
pKTol2C-EGFP plasmid.33 The EGFP sequence was replaced with custom-synthesized or 
PCR-amplified SOX5 sequences (primers are available upon request). Plasmid integrity was 
verified using Sanger sequencing. 
 
SOX5 immunolocalization 
HEK-293 cells (ATCC® CRL-1573™) were plated on glass coverslips and transfected with 
pKTol2C-SOX5 plasmids (2 μg) and Lipofectamine 2000 Transfection Reagent (Thermo 
Fisher Scientific). Two days later, they were stained using Image-ITTM LIVE Plasma Membrane 
and Nuclear Labeling Kit (Thermo Fisher, I34406), fixed in 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100 in PBS (PBST), and blocked in PBST supplemented 
with 1% BSA and 22.5 mg/ml glycine. They were then incubated with rabbit polyclonal SOX5 
antibody (1:200, Abcam, ab94396), followed by goat anti-rabbit antibody (1:500, Alexa Fluor 
488, Invitrogen, A27034). After placing DAPI-containing Vectashield antifade mounting 
medium (Vector Laboratories), cells were imaged by confocal laser scanning microscopy (Zeiss 
LSM 780; 100x objective). 
 
Western blot, electrophoretic mobility shift (EMSA), and dimerization assays 
HEK-293 cells were plated in six-well dishes and transfected eight hours later with empty or 
SOX5 expression plasmid (1 µg) and FuGENE6 (3 μl, Promega). The next day, extracts were 
prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher 
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Scientific) and tested by western blotting using SOX5 antibody (1:1000) and horseradish 
peroxidase-conjugated goat anti-rabbit IgG (1:5000, Vector Biolabs). Signals were visualized 
using ECL Prime Western Blotting Detection Reagents (Amersham). EMSA was conducted 
using the same extracts, 10 fmoles [α-32P]-dCTP-labeled 2HMG probe and 1 μg poly(dG-
dC).poly(dG-dC), as described.34 Homodimerization was tested in western blots following cell 
extract incubation for 10 minutes with 0.01% glutaraldehyde. 
 
Reporter assay 
HEK-293 cells were transfected with FuGENE6 containing 150 ng pSV2Gal, 500 ng Acan 
[4xA1]-p89Luc reporter, 50 ng SOX9 expression plasmid, and 300 ng of plasmid encoding no 
protein, wild-type (WT) SOX5 and/or variant SOX5, as previously described.35 Forty hours 
later, cells were collected in Tropix Lysis buffer (Applied Biosystems) with protease inhibitor 
cocktail (Thermo Fisher Scientific) and tested using Dual-Light luciferase and E. coli -
galactosidase assays (Thermo Fisher Scientific). Reporter activities were calculated as means 
with standard deviation of luciferase values measured for triplicates and normalized for 
transfection efficiency using -galactosidase values. 
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RESULTS 
The SOX5 variant spectrum associated with LAMSHF includes missense variants 
We collected genetic and clinical information from 41 patients (Table 1, supplementary table 
1). Eight patients (D1-D8), representing seven families, carried novel pathogenic 
microdeletions. These microdeletions ranged from 43.7 kb to 1.7 Mb and involved different 
breakpoints (Fig. 1a). While the largest deletion encompassed the entire SOX5 gene and its 5’ 
neighbor (BCAT1), the others were restricted to various segments of SOX5. 
  The other 33 patients belonged to 31 families and totaled 23 distinct point variants. 
Nineteen of these variants were classified by the InterVar interface as pathogenic or likely 
pathogenic (P1-P29) and the other four as variants of unknown significance (VUS) (V1-V4). 
Two patients had indels introducing frameshifts (P7 and P10) (Table 1, Fig. 1a and 1b). Two 
(P13 and P14) had variants altering the acceptor and donor splice sites of exon 12, respectively. 
Thirteen patients (including a pair of dizygotic twins) totaled eight distinct nonsense variants 
(P1-P6, P8-P10, P11, P12, P15, P25, and P28). Truncating variants (i.e., nonsense, splice site, 
and frameshift variants) were scattered over the L-SOX5 isoform from the N-terminus to the 
middle of the HMG domain. All altered SOX5 alleles thus encode proteins lacking DNA-
binding ability. Furthermore, since all variants spare the last exon, they likely trigger nonsense-
mediated mRNA decay and thus prevent protein expression. Sixteen patients (including a sib 
pair) had 11 different missense variants (P16-P24, P26, P27, P29, and V1-V4). Seven of these 
variants were clustered in the HMG domain, while the four VUS occurred in the first coiled 
coil (V1), between the coiled coils (V2), or after the HMG domain (V3 and V4). 
Five identical nucleotide transitions were identified in several unrelated individuals: 
c.622C>T, p.Gln208Ter (P2 and P3); c.637C>T, p.Arg213Ter (P4/P5 and P6); c.1477C>T, 
p.Arg493Ter (P11 and P12); c.1678A>G, p.Met560Val (P16 and P17); and c.1711C>T, 
p.Arg571Trp (P19 to P23). Besides a few that were of unknown inheritance, these alterations 
were all de novo and thus suggested the presence of hot spots for nucleotide transitions. Of 
additional note, 17 of 22 single nucleotide variants identified in patients are C>T and G>A 
transitions, suggesting that many SOX5 point variants result from cytosine deamination, a 
prevailing mechanism of genetic alteration.36 
 
High rate of parental mosaicism 
Most microdeletions and variants predicted to be pathogenic or likely pathogenic were 
undetected in parental blood samples, suggesting de novo occurrence (25/34 families, 74%). 
However, in each of three families, the same alteration was found in two affected siblings (D6 
and D7; P4 and P5; and P22 and P23), but not in their parents, and in two other patients (D3 
and P9), the variant was present at low levels in maternal blood. In addition, one nonsense 
variant was transmitted to a patient (P1) from his affected mother, where it was de novo. Variant 
transmission could not be determined for four patients (D1, P7, P12, P19) due to unavailability 
of parental samples. These findings thus indicate that pathogenic LAMSHF variants are 
frequently inherited from a mosaic parent (5/34, 15%) and also occasionally from an affected 
parent (1/34, 3%). 
 
Wide clinical spectrum associated with SOX5 pathogenic alterations 
Excluding the four patients with VUS, our patient series comprised 20 females and 17 males 
(Supplementary Table 1). The patients were 12.2 years of age on average at the time of 
examination (median: 8.0 years, range: 1.75-36), with 11 older than 15 and six younger than 
four.  
For most patients, pregnancy and delivery were unremarkable (21/36), birth 
measurements (weight, length and head circumference) normal (15/18 for whom full 
information was available), and the neonatal period uneventful (25/36). Eight patients had mild 
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growth retardation or a small head at birth, two were hypotonic, and three had feeding 
difficulties. 
Developmental delay was present in all patients for whom information was available. 
Although more than half of the patients timely acquired the sitting position (≤9 months; 
n=16/29), the age of walking was delayed in all but one (>18 months; n=35/36), without clear 
timing differences among variant categories (Fig. 2a, b). The age of first words was delayed in 
21/26 patients (>12 months; mean: 29.9 months, range: 10-60 months). The delay was 
significantly less pronounced in patients with missense variants (mean: 22.4 months, n=11) 
than in those with deletions and truncating variants (mean: 35.2 months, n=15; p-
value: 0.04, Wilcoxon rank sum test) (Fig. 2c). The levels of verbal expression were variable, 
but most patients older than three years could make short or full sentences (Supplementary 
Tables 1 and 2). 
Intellectual disability (ID) was reported in 30/33 patients, with 27 having mild-to-
moderate ID and three having severe or moderate-to-severe ID. The three patients without ID 
had learning difficulties and either borderline functioning or discrepant verbal/performance IQ 
scores. No significant correlation was observed between degree of ID and variant type (Fig. 
2d).  
Of 25 patients evaluated for autism spectrum disorder (ASD), six (four with truncating 
variants and two with missense variants) were positively diagnosed (24%) and 11 had other 
behavioral disturbances including stereotypies, isolation, tantrums and hyperactivity (Fig. 2e). 
Of 36 patients, eight experienced epileptic seizures (22%), but five of these had only one or two 
episodes and did not require medication. One of these patients (D6) had seizures triggered by 
environmental photosensitivity, an unusual finding in a “developmental delay plus seizures” 
syndrome (Supplementary Fig. 1). No correlation was found between the occurrence of 
seizures and the SOX5 variant type (Fig. 2f).  
Clinical examination revealed that stature and weight were within normal range for most 
patients. Head circumference of both males (n=14) and females (n=15) was in the low but 
normal range (~ -1.5 SD) while two patients (P14 and P23) had microcephaly. Hypotonia was 
reported in 22 patients, and five had additional neurological features, including ataxia (n=2) or 
pyramidal syndrome (n=3). Thirty-one patients had mild dysmorphic facial features, including 
broad/full nasal tip (n=9), thin upper lip or full lips (n=8), small jaw or chin (n=5), long face 
(n=3) or epicanthus (n=3). Strabismus was reported in 13 patients, optic atrophy in five, and 
amblyopia or cortical visual impairment in one each. Except for thin optic nerves, brain MRI 
scans were normal or showed nonspecific anomalies. Besides dysmorphic facial features, other 
skeletal malformations included scoliosis in six patients, thoracic kyphosis and hip dysplasia in 
one patient each, and fused cervical vertebrae in two patients (Supplementary Table 1). 
Malformations of other organs were rare and restricted to individual patients. Again, no 
correlation was found between the occurrence of these features and the variant types. Moreover, 
patients with recurrent variants (e.g. P2-P3: p.Gln208Ter, P4-P6: p.Arg213Ter, P16-P17: 
p.Met560Val, and P19-P23: p.Arg571Trp) exhibited considerable clinical variability, 
indicating that factors other than the SOX5 variants modulate the expression of the clinical 
phenotype. 
 
SOX5 is tightly conserved in the general population 
We used gnomAD, a genomic database for over 140,000 individuals that are theoretically 
unrelated and lacking severe pediatric disease, to investigate conservation constraints on SOX5 
in humans.37 While 158 synonymous variants were predicted and 159 were observed (Z score: 
-0.08), 42 loss-of-function variants were expected, but only three were observed (probability of 
loss-of-function intolerance, pLI= 1). Moreover, 427 missense variants were predicted, but only 
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244 were observed (Z score: 3.21). Thus, SOX5 is under tight-conservation constraint in control 
populations. Interestingly, gnomAD synonymous variants were found for 10-29% residues both 
within and outside functional domains, whereas missense variants altered significantly fewer 
residues in the HMG domain (six residues, i.e., 7.5%) than in other regions (21-33%) and 
significantly fewer than synonymous variants (20%, p=0.017) (Fig. 3a, b). The SOX5 HMG 
domain is thus highly constrained within control populations, which is in contrast to the 
relatively high prevalence of HMG-domain missense variants observed in our patient cohort. 
The first coiled-coil domain also had significantly fewer missense variants (20.7%) than the 
regions outside of known functional domains (33.2%; p=0.03), suggesting that this domain, 
which is required for SOX5 homodimerization and thereby for binding to pairs of recognition 
sites in target genes, is also under conservation constraint. 
 The six HMG-domain missense variants found in gnomAD affected two of the same 
residues as in LAMSHF patients and four others, and all six occurred only once 
(Supplementary Table 5). In contrast, for missense variants located outside the HMG domain, 
we found four occurrences of the patient Arg235Cys variant (located in the first coiled coil) in 
gnomAD, and one for Ser693Leu. Other gnomAD variants affected the same residues as in 
patients, such as Arg235His, found in 11 individuals. These observations suggest that some 
SOX5 variants, especially those located outside the HMG domain, may be better tolerated than 
others.  
 
In silico prediction of variant pathogenicity 
To predict pathogenicity of SOX5 missense variants, we first examined the location and 
conservation of affected residues. Since all HMG-domain residues are fully or semi-conserved 
in SOX5 vertebrate orthologs (Supplementary Fig. 2a), we focused on human SOX protein 
paralogs. All HMG-domain residues altered in patients and gnomAD individuals affected 
residues involved in DNA binding or bending, -helical configuration, or nuclear trafficking 
(Fig. 3c). Interestingly, three of the five residues altered in patients (Met560, Asn561 and 
Arg571) were among 23 residues identical in all protein paralogs, Tyr605 was among 13 semi-
conserved residues, and only Ala596 was among the 40 non-conserved residues. Conversely, 
only two of the six residues altered in gnomAD individuals were among the conserved and 
semi-conserved ones. Outside the HMG domain, patient variants affected residues that are 
highly conserved in SOX5 and its orthologs (Supplementary Fig. 2b). When the comparison 
was limited to human SOXD proteins (SOX5, SOX6 and SOX13), these conservation patterns 
held strongly for Arg235Cys, located in the first coiled-coil domain, and Thr632Asn, 
immediately flanking the HMG domain, but less strongly for residues located in functionally 
unknown regions (Fig. 3d). Together, these data suggested that all HMG-domain variants and 
a few other patient variants might impact SOX5 function. 
 We then asked whether the HMG-domain residues altered in LAMSHF patients also 
cause disease when altered in other SOX genes. Interestingly, all residues affected in LAMSHF 
patients were shown to cause gonadal dysgenesis or XY sex reversal when altered in SRY, or 
campomelic dysplasia with or without XY sex reversal when altered in SOX9 (Supplementary 
Table 6). In contrast, only two of the four variants found in gnomAD, but not in LAMSHF 
patients, were shown to cause disease when altered in SRY. These data further support 
pathogenicity of patient variants. They also suggest that some variants present in gnomAD 
individuals could be pathogenic, but clinical information was unavailable to validate this 
possibility.  
 Lastly, comparison of WT and variant residues using HOPE (Supplementary Fig. 3) 
showed that all variants differed from WT residues by at least one major structural feature: 
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16/18 differed in size; 13/18 differed in hydrophobicity; and 6/6 had a neutral instead of positive 
charge. All variants could thus affect the secondary structure and hence function of SOX5. 
 Overall, these analyses concurred that most missense variants identified in our patient 
series are likely pathogenic. 
 
Truncating variants and missense variants located within or near nuclear import signals 
impair SOX5 translocation to the nucleus 
We constructed expression plasmids for WT and variant forms of L-SOX5 and transiently 
transfected them in HEK-293 cells to explore the functional impacts of variants. Western blots 
of nuclear and cytoplasmic fractions (Fig. 4a) and cell immunostaining assays (Fig. 4b) showed 
that WT SOX5 localized primarily in the nucleus, as expected. On the contrary, expression of 
nonsense variants (Gln208Ter, Gln274Ter, Gly354Ter, and Arg493Ter) revealed that, if these 
variants were expressed in patients’ cells (i.e., if their mRNAs were not subjected to nonsense-
mediated decay), they would be primarily cytoplasmic. This result was expected since protein 
truncation occurs before the nuclear translocation signals. All proteins with a missense variant 
that we tested were able to translocate into the nucleus, except those in which the variant 
occurred within or near the N-terminal nuclear import signal. Accordingly, the Met560Val 
variant was localized to both the cytoplasm and nucleus, and the Asn561His and Arg571Trp 
variants were mainly cytoplasmic. Cytoplasmic retention of these missense variants may thus 
contribute to pathogenicity. 
 
Missense variants in the HMG domain prevent SOX5 from participating in 
transactivation 
We tested the transcriptional activity of SOX5 variants by transfecting HEK-293 cells with an 
Acan reporter whose enhancer is synergistically activated by SOX9 and SOXD proteins.35 WT 
SOX5 increased transactivation by SOX9 in a dose-dependent manner (Fig. 4c). Nonsense and 
HMG-domain missense variants exhibited little if any activity, whereas missense variants 
located outside the HMG domain had activity similar to WT. Since SOX5 variants are 
heterozygous in our patients, we also tested whether they could interfere with the activity of 
WT SOX5. Nonsense and HMG-domain missense variants did not affect the activity of WT 
SOX5, and missense variants located outside the HMG domain increased the reporter activity 
as much as WT SOX5 (Fig. 4d). Thus, none of the variants showed a dominant-negative effect. 
 We then tested the DNA-binding ability of SOX5 missense variants in EMSA using 
whole-cell extracts from HEK-293 cells transfected with SOX5 plasmids and a probe avidly 
binding SOXD homodimers.38 HMG-domain missense variants failed to bind DNA, whereas 
other missense variants efficiently bound DNA (Fig. 4e). This result also suggested that 
Arg235Cys, located in the main coiled-coil domain, can homodimerize effectively. Its ability 
to homodimerize was confirmed in an assay where closely interacting proteins were crosslinked 
with glutaraldehyde (Fig. 4f). 
 In conclusion, HMG-domain missense variants prevented SOX5 from binding DNA 
and from participating in transcriptional activation, supporting their pathogenicity. On the 
contrary, variants located outside the HMG domain had no deleterious impact in the assays 
used, but this finding does not rule out that they could be pathogenic and alter other, untested 
SOX5 activities. 
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DISCUSSION 
LAMSHF syndrome was previously described in just over two dozen patients. Most patients 
had deletions of at least part of SOX5, and a few had either a chromosomal translocation 
involving SOX5, or SOX5 nonsense or frameshift variants.9-12,19-21 Our patient series more than 
doubles the number of cases described in the literature and demonstrates that SOX5 missense 
variants clustering in the HMG domain can also cause LAMSHF syndrome. All variants were 
heterozygous, and most were predicted in silico and validated in vitro to be loss-of-function 
variants. This confirms that SOX5 haploinsufficiency is deleterious for neurogenesis and a few 
other developmental processes. Our study also revealed that parental mosaicism, found in at 
least 14% of families in our series, is relatively frequent in LAMSHF syndrome. This finding 
is important for genetic counseling and in line with increasing evidence that somatic, 
gonosomal, or gonadal mosaicism in parents may cause recurrence of neurodevelopmental 
disorders, apparently due to de novo variants.39 SOX5 and LAMSHF syndrome thus expand the 
list of such genes and disorders. 
Our extended study allowed further definition of the LAMSHF clinical features. ID is 
mostly within the mild-to-moderate range, and some cases have specific cognitive deficits 
rather than ID9. Delays in motor and language acquisition are observed in all patients and 
correlate with the level of ID. Behavioral disturbances are frequent and include ASD or autistic 
traits, as previously reported.9,10,40 Microcephaly is infrequent; yet, brain growth seems 
frequently mildly altered. Hypotonia is common, whereas other neurological features are 
infrequent. Our findings also suggest that SOX5 pathogenic variants predispose to epilepsy, 
with a prevalence of an order of magnitude higher than in the general population. Seizures in 
SOX5 patients usually respond well to antiepileptic treatments and follow a benign course. 
Ophthalmologic features, including strabismus, optic nerve atrophy, amblyopia and cortical 
visual impairment, are frequently observed9,19,22 and, together with rare skeletal malformations 
(i.e., scoliosis and fused cervical vertebrae), constitute corroborating rather than defining 
features of LAMSHF syndrome.9 The incomplete penetrance observed for some features 
suggests that SOX5 haploinsufficiency manifests differently in distinct individual genetic 
backgrounds or that some variants retain partial activity. The investigation of clinical features 
according to variant types, however, did not reveal clear genotype/phenotype correlations. 
Patients with HMG-domain missense variants tended to have milder language deficits, but this 
finding requires confirmation with larger patient cohorts. Based on the lack of obvious 
genotype-phenotype correlations and on the observation of variable phenotype severity in 
unrelated individuals with identical SOX5 variants, we tentatively conclude that yet-
unidentified factors significantly contribute to the penetrance and degree of disease severity.  
We also describe in this study four patients with de novo variants located outside the 
HMG domain and altering amino acids conserved in SOX5 orthologs. However, the 
pathogenicity of these variants could not be established through functional assays, and it thus 
remains unclear whether and how these variants contribute to disease in these patients. Three 
of these patients (V2 to V4) had phenotypic features compatible with LAMSHF syndrome 
(although patient V2 was very young at the time of the study and patient V3 mainly had ASD), 
whereas the fourth patient (V1) had Tourette syndrome. The variant identified in the latter 
patient (Arg235Cys) was also present in four gnomAD individuals from different ethnicities. 
Although Tourette patients are included in gnomAD ‘neuro’ cohorts, the individuals with 
Arg235Cys were not in these cohorts, suggesting that these individuals had no obvious 
neurological phenotype. Further investigations are therefore warranted to investigate whether 
missense variants outside the HMG domain could impair untested activities of SOX5 and 
whether these variants could predispose to LAMSHF or Tourette syndrome. 
In conclusion, our study demonstrates that the genetic and clinical spectrum in 
LAMSHF syndrome is much larger than previously described, and extends to missense variants 
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clustering in the HMG domain. In silico and in vitro functional data support the concept that 
these missense variants are pathogenic by causing loss of function of the SOX5 transcription 
factor, and thereby reflect gene haploinsufficiency during neurogenesis and occasionally during 
other developmental processes. The impacts of variants located outside the HMG domain 
remain to be determined. 
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Table 1. Summary of genetic and clinical data  
ID 
Family 
history 
Age 
(yrs) 
Sex 
SOX5 variant 
(NM_006940) 
Variant 
type 
Inheritance 
ACMG 
class 
Language 
delay 
Language 
ability 
ID (level) 
Behavioral 
disturbances 
Seizures Other features 
D1 spo 6.5 M del ex1 Del unknown 5 Y 10 words  Y (mild) NA N hypotonia 
D2 spo 10 M del ex5-10 Del DN 5 Y NA Y (moderate) 
intolerant 
to frustration, 
heteroaggressive 
N 
strabismus, hypotonia, fused 
vertebrae 
D3 spo 14 F del ex6-15 Del mat mosaic 5 Y sentences Y (mild) NA N strabismus 
D4 spo 5.5 F 
whole gene del 
(+BCAT1) 
Del DN 5 Y NA Y (moderate) NA N hypotonia 
D5 spo 10   F del ex6-8 Del DN 5 Y 
short 
sentences 
Y (moderate) NA N strabismus 
D6 sib 26 F del ex8-10 Del  mosaic 5 NA NA NA N Y 
fused vertebrae, subaortic 
ventricular septal defect, 
pulmonary stenosis 
D7 sib 36 M del ex8-10 Del  mosaic 5 Y sentences 
N 
(dyspraxia) 
NA Y none 
D8 spo 24 M del ex10-15 Del DN 5 Y sentences Y (moderate) 
autistic features, 
blinking, phobia 
N 
vesico-ureteral reflux, 
strabismus, amblyopia, pyramidal 
syndrome, toe syndactyly 
P1 mat 2.5 M 
c.518G>A, 
p.(Trp173Ter) 
NS 
mat 
(DN in 
mother) 
5 Y 20 words 
Y (mild-
moderate) 
stereotypies, 
intolerant to 
frustration 
N strabismus, hypotonia 
P2 spo 7 F 
c.622C>T, 
p.(Gln208Ter) 
NS DN 5 Y words Y (mild) NA N none 
P3 spo 3 F 
c.622C>T, 
p.(Gln208Ter) 
NS  DN 5 Y words NA NA NA hypotonia, café au lait spots 
P4 sib 31 F 
c.637C>T, 
p.(Arg213Ter) 
NS  mosaic 5 Y sentences Y (mild) 
isolated, shy, 
anxious 
N 
strabismus, optic atrophy, 
saccadic pursuit, tetrapyramidal 
syndrome,  scoliosis 
P5 sib 31 M 
c.637C>T, 
p.(Arg213Ter) 
NS  mosaic 5 Y sentences Y (mild) 
aggressive, 
agitated 
N 
saccadic pursuit, tetrapyramidal 
syndrome, scoliosis 
P6 spo 17.8 F 
c.637C>T, 
p.(Arg213Ter) 
NS DN 5 Y sentences 
N (borderline 
IQ) 
NA N 
strabismus, myopia, optic atrophy, 
hypotonia, gait instability, 
dysmetria  
P7 spo 2.5 F 
c.747_748del , 
p.(Arg250ThrfsTer36) 
FS unknown 5 Y nonverbal NA NA N strabismus, hypotonia 
P8 spo 8 M 
c.820C>T, 
p.(Gln274Ter) 
NS DN 5 Y 
short 
sentences 
Y (mild-
moderate) 
ASD, intolerant 
to frustration 
N 
strabismus, hypotonia, ear tubes, 
undescended testicles 
P9 spo 7 F 
c.1411C>T, 
p.(Arg471Ter) 
NS mat mosaic 5 Y 
associates 
words 
Y (mild-
moderate) 
ADHD N feeding difficulties, hypotonia 
P10 spo 8 M 
c.1465dup, 
p.(Leu489ProfsTer3) 
FS DN 5 Y words NA ASD N none 
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P11 spo 3 F 
c.1477C>T, 
p.(Arg493Ter) 
NS DN 5 Y words Y (moderate) NA N 
hypotonia, cortical visual 
impairment, ear tubes, scoliosis, 
constipation, supernumerary 
nipple 
P12 spo 20 M 
c.1477C>T, 
p.(Arg493Ter) 
NS unknown 5 Y nonverbal Y (severe) NA Y scoliosis 
P13 spo 12 F c.1489-1G>A, p.? splice  DN 5 Y sentences Y (moderate) ASD, anxious N 
hypotonia, constipation, thoracic 
kyphosis 
P14 spo 8 F c.1597+2T>A, p.? splice DN 5 Y 
>100 
words 
Y (moderate) NA 
N (EEG 
anomalies) 
hypotonia, right microtia, 
microcephaly, myopia 
P15 spo 30 M 
c.1613C>G, 
p.(Ser538Ter) 
NS DN 5 Y 
short 
sentences 
Y (moderate) autistic features Y none 
P16 pat 13 M 
c.1678A>G, 
p.(Met560Val) 
MS DN 5 Y sentences Y (mild) temper tantrums Y none 
P17 spo 1.75 F 
c.1678A>G, 
p.(Met560Val) 
MS DN 5 Y words Y (mild) NA N 
hypotonia, joint hyperlaxity, hip 
dysplasia 
P18 sib 4 M 
c.1681A>C, 
p.(Asn561His) 
MS DN 5 Y words Y (severe) insomnia N 
dysphagia with G-tube 
dependence, scoliosis, hypotonia, 
muscle weakness 
P19 spo 27 F 
c.1711C>T, 
p.(Arg571Trp) 
MS unknown 5 Y sentences Y (mild) NA N ovarian dystrophy 
P20 pat 17 M 
c.1711C>T, 
p.(Arg571Trp) 
MS DN 5 Y sentences Y (moderate) autistic features N none 
P21 mat 6 M 
c.1711C>T, 
p.(Arg571Trp) 
MS DN 5 Y 
short 
sentences 
Y (moderate) 
angry outbursts, 
stereotypies 
Y 
joint hyperlaxity, strabismus, 
hypotonia 
P22 sib 3.3 F 
c.1711C>T, 
p.(Arg571Trp) 
MS  mosaic 5 Y words 
Y (mild-
moderate) 
NA N hypotonia 
P23 sib 5.6 M 
c.1711C>T, 
p.(Arg571Trp) 
MS  mosaic 5 Y 
short 
sentences 
Y (mild-
moderate) 
ADHD N hypotonia, microcephaly 
P24 spo 18 F 
c.1712G>T, 
p.(Arg571Leu) 
MS DN 4 Y sentences Y (moderate) NA Y hypotonia 
P25 spo 4 F 
c.1782G>A, 
p.(Trp594Ter) 
NS  DN 5 Y babbles 
Y (moderate-
severe) 
ASD, sensory 
integration 
disorder 
N 
bilateral optic nerve atrophy, 
hypotonia 
P26 spo 14 F 
c.1786G>C,p. 
(Ala596Pro) 
MS DN 5 Y sentences Y (moderate) ASD, anxious Y 
teeth anomalies, strabismus, 
hypotonia, muscle weakness 
P27 spo 6.5 F 
c.1814A>G, 
p.(Tyr605Cys) 
MS DN 5 Y sentences 
Y 
(borderline-
mild) 
ASD N 
constipation, optic atrophy, joint 
hyperlaxity, hypotonia 
P28 spo 5.5 M 
c.1819G>T, 
p.(Glu607Ter) 
NS DN 5 Y sentences 
N (VIQ/PIQ 
discrepancy) 
NA N 
ear tubes, pallor of left optic 
nerve, strabismus, constipation, 
hypotonia 
P29 spo 4 M 
c.1868A>G, 
p.(Tyr623Cys) 
MS DN 4 Y words Y (mild) NA N gait ataxia 
V1 spo 18 M 
c.703C>T, 
p.(Arg235Cys) 
MS DN 3 NA NA N NA N Tourette syndrome 
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V2 spo 0.7 M 
c.928T>A, 
p.(Cys310Ser) 
MS DN 3 NA NA NA NA Y 
severe obstructive sleep apnea, 
severe gastroesophageal reflux, G-
tube fed, hypotonia 
V3 spo 13 M 
c.1895C>A, 
p.(Thr632Asn) 
MS DN 3 Y words 
Y (moderate-
severe) 
ASD N none 
V4 spo 36 M 
c.2078C>T, 
p.(Ser693Leu) 
MS DN 3 Y 
short 
sentences 
Y (moderate) NA Y none 
IDs: D, pathogenic microdeletion; P, pathogenic or likely pathogenic variant; V, variant of unknown significance. ACMG class: 5, 
pathogenic; class: 4, likely pathogenic; 3, variant of uncertain significance. ADHD: attention deficit hyperactivity disorder; ASD: 
autism spectrum disorder; M: male; F: female; ex: exon(s); Del: deletion; FS: frameshift; MS: missense; NS: nonsense; DN: de novo; 
spo: sporadic; mat: maternal; pat: paternal; sib: sibling (affected sib pairs); NA: not available; N: no; Y: yes; yrs: years. See 
supplementary table 1 for more details.
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Fig. 1. SOX5 variant spectrum associated with LAMSHF syndrome. 
(a) Location of genetic alterations identified in patients in this study. SOX5 transcript isoforms are labeled with NCBI 
accession numbers. Boxes 1 to 15, coding exons of isoform NM_006940. 5’ and 3’UTR: 5’ and 3’ untranslated 
sequences. p1 to p11 represent SOX5 promoters listed in the Fantom5 database; p1 and p2 (in bold) are the main 
promoters driving SOX5 expression in brain. CC, coiled-coil domain. Double-arrowed lines, deletions in patients D1-
D8. Point variants, labeled as indicated.  
(b) Location of point variants reported here (above) and previously (below) on the longest SOX5 isoform. Protein and 
domain residue boundaries are indicated underneath the schematic. Red, nonsense and frameshift variants. Blue and 
green, missense variants within and outside the HMG domain, respectively. Superscripts, references.  
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Fig. 2. Patients exhibit similar clinical features regardless of the SOX5 alteration type. 
Box plots showing comparative distribution of ages at (a) sitting unsupported, (b) walking unsupported, and (c) first 
words for patients with deletion, truncating and missense variants. (d) Number of patients with normal to borderline 
cognitive abilities and various degrees of ID. (e) Number of patients with autism spectrum disorder or other behavioral 
disturbances. (f) Number of patients with seizures. (g) Facial profiles of individuals with de novo SOX5 variants. 
Above: D2 at age 10 years; D6 at age 26 years; D8 at age 24 years. Center: P1 at age 2 years, and his mother (41 years 
old); P6 at age 19 years; P10 at age 8 years. Below: P13 at ages 2 years, 6 months, and 11 years, 4 months, respectively; 
P14 at ages 2 years, 4 months and 8 years, respectively; P25 at age 4 years; P28 at age 5 years. Common facial features 
include broad or full nasal tip, thin upper lip and/or full lower lips, small jaw or prominent chin, prominent upper 
incisors and epicanthus.  
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Fig. 3. Human SOX5 is under tight conservation constraint. 
(a) Distribution of synonymous and missense variants in SOX5 in gnomAD individuals. 
(b) Percentages of residues carrying at least one synonymous or missense variant in the functional and other domains 
of SOX5 in gnomAD individuals. T-tests were performed to calculate the statistical significance of differences 
between protein domains. P values are indicated. 
(c) Alignment of all human SOX protein HMG domain sequences, with indication of residues altered in LAMSHF 
patients (red) and altered only in gnomAD individuals (purple). Asterisks, fully conserved residues. Dots, semi-
conserved residues. Colored triangles, residues important for DNA binding and bending. Brackets, H1, H2, and 
H3 -helices. Continued lines and linked with dotted lines, key amino acids in nuclear localization signal 
sequences (NLS) and nuclear export signal sequence (NES).  
(d) Alignment of human SOXD protein sequences outside the HMG domain that encompass residues altered in 
LAMSHF patients.  
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Fig. 4. Subcellular localization and activities of SOX5 variants.  
(a) Western blots of cytoplasmic (C) and nuclear (N) extracts from HEK-293 cells transfected with plasmids encoding 
no protein (-), wild-type SOX5 (WT) or SOX5 variants. Blots were incubated with SOX5 antibody. Red boxes, 
SOX5-specific protein signals. Numbers, Mr of protein standards.  
(b) Representative images of SOX5 immunostaining (green signal) in HEK-293 cells transfected with plasmids 
encoding wild-type SOX5 (WT) or the indicated variants. Nuclei are seen blue and plasma membranes in red. 
Scale bars, 20 μm. 
(c) Test of the abilities of SOX5 variants to synergize with SOX9 in transactivation. HEK-293 cells were transfected 
with Acan and pSV2Gal reporter plasmids and plasmids encoding no protein, SOX9 and/or SOX5. The WT 
SOX5 plasmid was used in the indicated amounts, and the variant plasmids at 150 ng. Reporter activities are 
presented as the mean ± standard deviation obtained for triplicates in one representative experiment. They were 
normalized for transfection efficiency and are reported as increase over the activity of SOX9 alone. 
(d) Test of the abilities of SOX5 variants to interfere with WT SOX5 in transactivation. HEK-293 cells were 
transfected essentially as described above. SOX5 variant plasmids were tested at 150 ng with 150 ng SOX5 WT 
plasmid. Reporter activities were calculated and are presented as described above.  
(e) Test of the abilities of SOX5 variants to bind DNA in EMSA. Extracts from HEK-293 cells transfected with 
empty, WT SOX5 or SOX5 variant plasmid were incubated with a 2HMG DNA probe. Top, X-ray film images. 
SOX5/DNA complexes migrated more slowly than non-specific protein (non-sp.)/DNA complexes. Bottom, 
western blot showing similar amounts of all SOX5 proteins. 
(f) Dimerization assay with the same extracts as in panel c for no protein, WT SOX5, and the R235C variant. Western 
blots were performed using SOX5 antibody. SOX5 dimers ran in SDS-PAGE with an apparent Mr twice as large 
as that of monomers. 
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SUPPLEMENTARY FIGURES 
Supplementary Fig. 1. EEG recordings in patient D6. 
 
(a) EEG with photic stimulation at 14 Hz. Occipital spikes can be seen following eye closure. These are brief and do not outlast the 
stimulus.  
(b) An epoch of EEG with the eyes closed to demonstrate that this is not fixation off sensitivity during 1Hz photic stimulation
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Supplementary Fig. 2. Conservation of residues mutated in LAMSHF and gnomAD 
individuals in SOX5 orthologs. 
 
(a) Alignment of the HMG domain sequence of vertebrate SOX5 orthologs, with indication of 
residues altered in LAMSHF patients (red) and altered only in gnomAD individuals (purple). 
Asterisks, fully conserved residues. Dots, semi-conserved residues. Colored triangles, residues 
important for DNA binding and bending. Brackets, H1, H2, and H3 -helices. Continued lines 
and linked with dotted lines, key amino acids in nuclear localization signal sequences (NLS) 
and nuclear export signal sequence (NES).  
(b) Alignment of vertebrate SOX5 ortholog sequences encompassing residues altered in LAMSHF 
patients.  
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Supplementary Fig. 3. Analysis of amino-acid property differences between wild-type (WT) 
and variant residues. 
 
Schematic of amino acids present in WT SOX5 (labeled in blue) and in variant proteins detected 
in LAMSHF patients (red) and in gnomAD individuals (purple). The relative size, charges and 
hydropathy scores of each residue are indicated. 
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SUPPLEMENTARY TABLES 
 
Supplementary table 1. Complete molecular and clinical features of the 41 patients with 
SOX5 variants included in this study (excel format). 
 
Supplementary table 2. Comparison of developmental milestones, ID levels and additional 
features according to variant type. 
Variant types 
Missense 
variants 
Truncating 
variants 
Deletions All 
Age of sitting  
(months) 
mean 11.1 12.1 9.2 11.2 
median 9.0 10.0 9.0 9.0 
n= 11 13 5 29 
Age of walking 
(months) 
mean 25.8 25.7 22.0 24.9 
median 26.0 23.5 20.5 23.0 
n= 12 16 8 36 
Age of first words 
(months) 
mean 22.4 38.2 31.0 29.9 
median 18.0 36.0 30.0 29.0 
n= 11 9 6 26 
Current language ability 
(>3y) 
nonverbal 0 2 0 2 
words 3 2 1 6 
associated words 0 2 0 2 
short sentences 2 2 1 5 
full sentences 6 5 3 14 
 total n= 11 13 5 29 
ID 
no ID/borderline IQ 0 2 1 3 
borderline-mild 1 0 0 1 
mild 4 3 2 9 
mild/moderate 2 3 0 5 
moderate 4 4 4 12 
moderate/severe 0 1 0 1 
severe 1 1 0 2 
total n= 12 14 7 33 
ASD or autistic traits   4/11 5/14 1/6 10/32 
Seizures  4/16 2/12 2/8 8/36 
Ophthalmological features  3/12 8/16 4/8 15/36 
Skeletal features  2/12 4/16 2/8 8/36 
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Supplementary table 3. Accession numbers for the human SOX sequences aligned in Fig. 3. 
  Protein  Reference sequence 
  SRY  CAA37790.1 
  SOX1  NP_005977.2 
  SOX2  NP_003097.1 
  SOX3  NP_005625.2 
  SOX4  AAH72668.1 
  SOX5   AAH60773.1 
  SOX6  AAK26115.1 
  SOX7   CAC84226.1 
  SOX8  NP_055402.2 
  SOX9  CAA86598.1 
  SOX10 CAG38808.1 
  SOX11 BAA88122.1 
  SOX12 AAH67361.1 
  SOX13 AAD50120.1 
  SOX14 AAC95380.1 
  SOX15 AAH72003.1 
  SOX17 BAB83867.1 
  SOX18 BAA94874.1 
  SOX21 AAC95381.1 
  SOX30 BAA37146.1 
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Supplementary table 4. Accession numbers for the SOX5 ortholog sequences aligned in Fig. 
S1. 
Vertebrate species   Scientific name  Reference sequence 
Human    Homo sapiens   AAH60773.1 
Olive baboon    Papio Anubis   XM_021923256.1 
Thirteen-lined ground squirrel  Ictidomys tridecemlineatus XM_021728812.1 
House mouse    Mus musculis   AAI10479.1 
European rabbit   Oryctolagus cuniculus  XM_008259535.2 
Common bottlenose dolphin  Tursiops truncatus   XM_019936434.1 
Cattle (cow)    Bos taurus    AAI14659.1 
Horse     Equus caballus   XP_014596142.2 
Little brown bat   Myotis lucifugus  XP_006090714.1 
European hedgehog   Erinaceus europaeus   XM_007517901.1 
African bush elephant   Loxodonta Africana   XP_023410581.1 
Platypus     Ornithorhynchus anatinus XP_007671116.1 
Red junglefowl (chicken)  Gallus gallus   NP_001004385.1 
Painted turtle    Chrysemys picta bellii XM_008165618.2 
Western clawed frog   Xenopus tropicalis   AAI67694.1 
Japanese puffer (fugu)  Takifugu rubripes  XM_011618714.1 
Zebrafish    Danio rerio    NP_001028757.1 
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Supplementary table 5. GnomAD missense variants present in the same residues as in 
LAMSHF patients (top) and in the HMG domain (bottom)  
SOX5 Domain Variant  LAMSHF gnomAD  Other gnomAD variants 
1st CC  R235C  1x  4x   R235H, 11x 
1st-2nd CC C310S  1x  -  C310F, 1x 
HMG  M560V  2x  -  - 
HMG  N561H  1x  -  - 
HMG  R571L & W 1x & 4x -  R571Q, 1x 
HMG  A596P  1x  -  A596S, 1x 
HMG  Y605C  1x  -  - 
C-terminus T632N  1x  -  - 
C-terminus S693L  1x  1x  - 
HMG  H555Y  -  1x  - 
HMG  R593C  -  1x  - 
HMG  L600V  -  1x  - 
HMG  P629S  -  1x  - 
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Supplementary table 6. Disease-causing missense variants in SRY and SOX9 residues 
matching SOX5 HMG-domain variants identified in LAMSHF patients and gnomAD 
individuals 
Protein Variant Phenotype Reference 
SOX5  p.His555Tyr  Unknown  GnomAD 
SRY  p.Arg59Gly  Gonadal dysgenesis 41 
 
SOX5  p.Met560Val  LAMSHF syndrome This study 
SRY  p.Met64Ile  Gonadal dysgenesis 42 
  p.Met64Arg  Gonadal dysgenesis 43 
 
SOX5  p.Asn561His  LAMSHF syndrome This study 
SRY  p.Asn65Asp  Gonadal dysgenesis 44 
  p. Asn65His  Gonadal dysgenesis 45 
 
SOX5  p.Arg571Leu  LAMSHF syndrome This study 
  p.Arg571Trp  LAMSHF syndrome This study 
  p.Arg571Gln  Unknown  GnomAD 
SRY  p.Arg76Ser  XY sex reversal 46 
  p.Arg76Pro  Gonadal dysgenesis 47 
  p.Arg76Thr  Gonadal dysgenesis 48 
SOX9  p. Arg120Cys  Campomelic Dysplasia (CD) 49 
 
SOX5  p.Arg593Cys  Unknown  GnomAD 
 
SOX5  p.Ala596Pro  LAMSHF syndrome This study 
  p.Ala596Ser  Unknown  GnomAD 
SRY  p.Leu101His  Hermaphroditism 50 
  p.Leu101Val  XY sex reversal 51 
 
SOX5  p.Leu600Val  Unknown  GnomAD 
 
SOX5  p.Tyr605Cys  LAMSHF syndrome This study 
SOX9  p.Phe154Leu  CD and XY sex reversal 52 
 
SOX5  p.Pro629Ser  Unknown  GnomAD 
SRY  p.Arg133Trp  Gonadal dysgenesis 48 
  p.Arg133Gly  XT sex reversal 53 
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